🔴 Arcturus Therapeutics is trading 5.2% down today — no clear company-specific catalyst identified

Arcturus Therapeutics is trading 5.2% down now at $14.82, with no clear company-specific catalyst identified for the September 9, 2026 decline.

• Management is participating in Citi’s Biopharma Back to School Summit; investors are focused on Phase II OTC-deficiency data expected later in September and a cystic-fibrosis go/no-go decision expected during the fourth quarter.
• Broader risk sentiment is weak, but available index moves do not clearly establish a market-wide cause.